Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine

Int Clin Psychopharmacol. 2000 Jan;15(1):57-60. doi: 10.1097/00004850-200015010-00010.

Abstract

In a single inpatient case study, a schizophrenic patient with tardive dyskinesia after prolonged treatment with typical neuroleptics was treated with the new atypical neuroleptic quetiapine, a dibenzothiazepin-derivative. Within 2 weeks of treatment with quetiapine, symptoms of tardive dyskinesia improved; 10 weeks after starting treatment tardive dyskinesia stopped completely. Over the same period, dopamine D2 receptor occupancy decreased substantially, as measured by IBZM-SPECT after 14 and 77 days of treatment.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antipsychotic Agents / adverse effects*
  • Antipsychotic Agents / therapeutic use*
  • Dibenzothiazepines / adverse effects*
  • Dibenzothiazepines / therapeutic use*
  • Dyskinesia, Drug-Induced / diagnostic imaging
  • Dyskinesia, Drug-Induced / therapy*
  • Humans
  • Male
  • Psychiatric Status Rating Scales
  • Quetiapine Fumarate
  • Receptors, Dopamine D2 / drug effects
  • Receptors, Dopamine D2 / metabolism
  • Schizophrenia / complications*
  • Schizophrenia / diagnostic imaging
  • Schizophrenia / drug therapy*
  • Schizophrenic Psychology
  • Tomography, Emission-Computed, Single-Photon

Substances

  • Antipsychotic Agents
  • Dibenzothiazepines
  • Receptors, Dopamine D2
  • Quetiapine Fumarate